13 Aug 2019

CHARITY CARE SPENDING BY CALIFORNIA HOSPITALS PLUNGES SINCE OBAMACARE WENT INTO EFFECT

 By Harriet Blair Rowan California hospitals are providing significantly less free and discounted care to low-income patients since the Affordable Care Act took effect. As a proportion of their operating expenses, the state’s general acute-care hospitals spent less than half on these patients in 2017 than they did in 2013, according

0
09 Aug 2019

MIND AND BODY: COORDINATING CARE MIGHT HELP MEDICAID SAVE MONEY AND LIVES

    By Blake Farmer Modern medicine often views the mind and body on separate tracks, both in terms of treatment and health insurance reimbursement. But patients with psychological disorders can have a hard time managing their physical health. So some Medicaid programs, which provide health coverage for people with low

0
12 Jul 2019

PAYER ANALYSIS: ‘CADILLAC TAX’ ON HIGH-COST HEALTH PLANS COULD AFFECT 1 IN 5 EMPLOYERS IN 2022

[/infobox]   A new KFF analysis estimates that the Affordable Care Act’s tax on high-cost health plans would affect one in five (21 percent) employers offering health benefits when it takes effect in 2022 unless employers change their health plans. An even larger share (31 percent) could be affected when workers’ voluntary

0
26 Jun 2019

 ANGIODYNAMICS SELLS NAMIC fluid management portfolio

AngioDynamics Inc., a provider of innovative, minimally invasive medical devices for oncology, vascular access and peripheral vascular disease, has agreed to sell its NAMIC fluid management portfolio to Medline Industries Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0
26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0
12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0
12 Jun 2019

MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly

0
11 Jun 2019

WHEN IT COMES TO OUR HEALTH – EVERY SECOND COUNTS

By Seema Verma Healthcare: American’s favorite debate topic.  While there is much to debate, we can all agree that the patient-provider relationship has been strained by unnecessary regulations and reporting requirements. Too much regulation has had the unintentional result of putting the government first and the patient second.  Time spent

0